Investors
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
press release
July 25, 2018
Geneva, Switzerland and Boston, MA – July 25, 2018– ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and…
Read morepress release
July 13, 2018
Trading of ObsEva’s shares on SIX Swiss Exchange starts under the ticker symbol ‘OBSN’ Reference price at CHF 15.00 per share ObsEva with unique…
Read morepress release
July 6, 2018
Listing of 45’381’252 registered shares with a par value of 1/13 of CHF 1 per share Anticipated market capitalisation of more…
Read moreJune 29, 2023
May 18, 2022
ObsEva Announces Update on Board of Directors
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 –…
Read moreMedia
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840